ONMDHIGH SIGNALFINANCIAL10-K

ONMD underwent significant financial restructuring with a 70% increase in outstanding shares, massive debt reduction of 90.5%, and substantial improvement in equity position despite continued operational losses.

The 70% increase in shares outstanding (from 30.8M to 52.2M) combined with the June 2025 private placement with James Sixsmith indicates significant dilution but also fresh capital injection. The dramatic reduction in total debt from $2.3M to $220K and improvement in stockholders' equity from -$15.9M to -$3.0M suggests a major balance sheet restructuring that has stabilized the company's financial position in the near term.

Comparing 2026-03-30 vs 2025-04-15View on EDGAR →
FINANCIAL ANALYSIS

ONMD's financials show a company emerging from financial distress through equity financing and debt restructuring. While revenue doubled from $643K to $1.4M, gross losses also increased significantly, and the company remains unprofitable with rising interest expenses. However, the dramatic 90.5% debt reduction, 81.4% improvement in stockholders' equity, and substantial decrease in current liabilities from $19.2M to $4.8M indicate successful financial restructuring that has bought the company time to execute its turnaround strategy, albeit at the cost of significant shareholder dilution.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
+240.1%
$172K$585K

Cash position surged 240.1% — strong cash generation or capital raise providing significant financial cushion.

Accounts Receivable
Balance Sheet
+132.4%
$213K$495K

Receivables surged 132.4% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Revenue
P&L
+111.4%
$643K$1.4M

Strong top-line growth of 111.4% — accelerating demand or successful expansion into new markets.

Total Debt
Balance Sheet
-90.5%
$2.3M$220K

Debt reduced 90.5% — deleveraging strengthens balance sheet and reduces financial risk.

Interest Expense
P&L
+85.8%
$403K$749K

Interest expense surged 85.8% — significant debt increase or rising rates materially impacting earnings.

Stockholders Equity
Balance Sheet
+81.4%
-$15.9M-$3.0M

Equity base grew 81.4% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Gross Profit
P&L
-79%
-$281K-$503K

Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.

Current Liabilities
Balance Sheet
-74.9%
$19.2M$4.8M

Current liabilities reduced — improved short-term financial position and working capital health.

Capital Expenditure
Cash Flow
-74.5%
$51K$13K

Capex reduced 74.5% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Total Liabilities
Balance Sheet
-74%
$19.7M$5.1M

Liabilities reduced 74% — deleveraging improves balance sheet strength and financial flexibility.

LANGUAGE CHANGES
NEW — 2026-03-30
PRIOR — 2025-04-15
ADDED
As of March 27, 2026, there were there were 52,196,729 shares of common stock, par value $0.0001 per share, issued and outstanding, and 0 shares of preferred stock, par value $0.0001 per share, of the registrant issued and outstanding.
These additional sources include the internet of things, social media forums and blogs.
Real World Evidence can be used to make clinical trials more effective and efficient, for example in patient recruitment or label extension.
Real World Evidence gathered from other studies or from currently marketed products in a similar category, for example, can have a positive effect on the product portfolio by exposing positive side effects as new potential indications.
12 Recent Developments Private Placements June 2025 Financing On June 19, 2025, we entered into a securities purchase agreement with James Sixsmith ( Mr.
+7 more — sign up free →
REMOVED
As of March 26, 2025, there were there were 30,760,576 shares of common stock, par value $0.0001 per share, issued and outstanding, and 0 shares of preferred stock, par value $0.0001 per share, of the registrant issued and outstanding.
These additional sources include the internet of things ( IoT ), social media forums and blogs.
Real World Evidence can be used to make clinical trials more effective and efficient, for example in patient recruitment or label extension, Real World Evidence gathered from other studies or from currently marketed products in a similar category, for example, can have a positive effect on the product portfolio by exposing positive side effects as new potential indications.
Recent Developments Closing of Business Combination On November 7, 2023, following the approval of the Merger Agreement and the transactions contemplated thereby at the special meeting of the shareholders of Data Knights held on October 17, 2023 (the Special Meeting ), Merger Sub merged with and into Legacy ONMD pursuant to the Merger Agreement (the Merger ), with Legacy ONMD surviving the Merger as a wholly-owned subsidiary of Data Knights.
Following Closing, Data Knights changed its name to OneMedNet Corporation.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →